Vimarsana
Biggest News Aggregation in the World

Page 3 - Accelerate Commercialization News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Accelerate Commercialization. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Accelerate Commercialization Today - Breaking & Trending Today

U.S. focus on Pfizer production could delay manufacturing of other COVID-19 vaccines, Serum Institute CEO warns - Vimarsana News

U.S. focus on Pfizer production could delay manufacturing of other COVID-19 vaccines, Serum Institute CEO warns

As the U.S. locks up supplies to make Pfizer's COVID-19 vaccine, Serum Institute of India and WHO are raising flags about global supply bottlenecks and raw materials shortfalls, Bloomberg reports. The supply disruption comes after the Biden administration tapped the Defense Production Act to increase deliveries of Pfizer's shot in the U.S.

Takeda keeps divestment spree rolling with $1.2B sale of diabetes meds to Japanese firm Teijin - Vimarsana News

Takeda keeps divestment spree rolling with $1.2B sale of diabetes meds to Japanese firm Teijin

Takeda's latest sale brings its total divestment value up to about $12.9 billion. (Takeda) After inking a slate of geography-specific product selloffs last year, Takeda has turned back to Japan. Takeda locked up a deal to sell four Type 2 diabetes meds in Japan to local drugmaker Teijin Pharma for 133 billion Japanese yen ($1.2 billion), freeing up the company to focus on its core businesses in gastroenterology, rare diseases, plasma-derived therapies, oncology and neuroscience. The move is the latest in Takeda's selloff spree, linked to a divesture goal it set alongside its Shire merger. The...

Pfizer's Lorbrena breaks into front-line ALK lung cancer, jostling with Novartis, Roche and Takeda - Vimarsana News

Pfizer's Lorbrena breaks into front-line ALK lung cancer, jostling with Novartis, Roche and Takeda

Mar 4, 2021 10:54am The FDA has expanded Pfizer's Lorbrena approval to include front-line ALK-positive non-small cell lung cancer. Pfizer’s Lorbrena has finally broken into front-line non-small cell lung cancer, where Novartis, Roche and Takeda are already jockeying for a niche market. The FDA expanded Lorbrena’s use into newly diagnosed patients with ALK-positive NSCLC, Pfizer said Wednesday. With that front-line nod, the agency converted Lorbrena's conditional green light for previously treated cases into a full approval. How does Pfizer expect to compete in such a crowded field? As a t...

Roche is gearing up to knock down an Irish plant—and it's complicated - Vimarsana News

Roche is gearing up to knock down an Irish plant—and it's complicated

Mar 4, 2021 11:33am Roche decided in 2015 to close four small-molecule manufacturing plants around the world. It found buyers for three. But the one that the company couldn't sell was in Clarecastle, Ireland. Destruction of the facility begins in June. (Roche) Unable to sell its plant in Clarecastle, Ireland, Roche will take a wrecking ball to the facility in June. It won’t be a simple process. In fact, a timeline of June 2021 to May 2028 has been listed for the project, which requires removing 10 buildings and infrastructure from the 88-acre site.  The most painstaking aspect of the ope...

Biogen cements gene therapy ambitions with $200M factory in Research Triangle - Vimarsana News

Biogen cements gene therapy ambitions with $200M factory in Research Triangle

Mar 4, 2021 11:10am Biogen plans to bring on 90 new employees to staff its planned gene therapy manufacturing facility. (Biogen) As Biogen awaits an FDA decision on its controversial Alzheimer's disease hopeful aducanumab, the company is setting the stage for an entry into the hot gene therapy field.  Biogen has drawn up plans for a new gene therapy manufacturing facility at its Research Triangle Park campus in North Carolina. The 175,000-square-foot facility will be designed to scale up the manufacturing of the products that are in Biogen's growing gene therapy pipeline. Biogen expects ...